Sopartec

Sopartec is a technology transfer and investment company affiliated with the Université catholique de Louvain, established in 1992 and based in Louvain-la-Neuve, Belgium. The firm focuses on facilitating the commercialization of innovations developed within the university and manages the Vives Louvain Technology Fund, which invests in spin-offs and startups emerging from the institution. Sopartec targets investments across various sectors, including consumer goods, finance, energy, healthcare, and technology, primarily within Belgium and neighboring countries. Through its initiatives, Sopartec aims to support the growth of promising ventures and enhance the impact of university research in the marketplace.

Xavier Bastin

CEO

Benoît Limage

CFO

3 past transactions

Cissoid

Series B in 2008
Cissoid S.A. specializes in the manufacture of high-temperature semiconductor solutions designed for power management, power conversion, and signal conditioning in extreme environments. Founded in 2000 and headquartered in Mont Saint Guibert, Belgium, Cissoid develops a diverse range of products including voltage regulators, isolated gate drivers, power switches, high-voltage silicon carbide power modules, and analog-to-digital converters. Their products are engineered to operate effectively from -55°C to +225°C, with testing extending to extreme temperatures of -200°C to +300°C. Cissoid’s offerings cater to various industries such as oil and gas, aerospace, automotive, and industrial sectors, helping these markets address challenges related to power density and efficiency. The company also provides custom solutions, utilizing Silicon-on-Insulator technology to enhance reliability and performance in harsh conditions. Through a network of distributors and representatives, Cissoid serves international markets across Asia-Pacific, Europe, the Middle East, Africa, and the Americas.

Viridaxis

Series B in 2007
VIRIDAXIS, a spin‑off of Louvain Catholic University, uses an innovative technology to mass-produce parasitoids. These are then supplied to Belgian and multinational companies operating in this sector. Expansion of its R&D activity now enables the company to develop new products and increase its production capacity.

Diatos

Series D in 2007
Diatos is a biopharmaceutical company founded in 1999 and headquartered in Paris, France with two subsidiaries in Leuven, Belgium and in the San Francisco Bay Area, USA. Diatos is focused on the research, development and marketing of new versions of existing anti-cancer chemotherapeutic drugs with enhanced tumor targeting or improved biodistribution. Diatos has built its portfolio of drugs and drug candidates through a strategy of license acquisitions as well as an internal research and development activity based on its prodrug technologies, Vectocell® and Tumor-Selective Prodrug (TSP).
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.